Carl D. Regillo, MD, FACS
Show Description +
Carl D. Regillo, MD, FACS, analyzes data from the Chroma and Spectri phase 3 lampalizumab (Roche/Genentech) trials with regard to the effect of baseline characteristics on the progression of geographic atrophy.
Posted: 7/20/2018
Carl D. Regillo, MD, FACS
Carl D. Regillo, MD, FACS, analyzes data from the Chroma and Spectri phase 3 lampalizumab (Roche/Genentech) trials with regard to the effect of baseline characteristics on the progression of geographic atrophy.
Posted: 7/20/2018
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ASRS: 2018.
Please log in to leave a comment.